Cipher Pharmaceuticals (TSE:CPH) Price Target Raised to C$17.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price boosted by equities research analysts at Stifel Nicolaus from C$16.00 to C$17.00 in a report released on Wednesday, BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 17.32% from the company’s previous close.

A number of other research firms also recently commented on CPH. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Leede Financial downgraded Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Price Performance

Shares of Cipher Pharmaceuticals stock traded down C$0.01 during trading hours on Wednesday, hitting C$14.49. The company’s stock had a trading volume of 24,675 shares, compared to its average volume of 45,568. The business has a 50 day moving average price of C$14.21 and a two-hundred day moving average price of C$10.57. Cipher Pharmaceuticals has a 12-month low of C$4.10 and a 12-month high of C$19.69. The company has a market cap of C$370.80 million, a PE ratio of 11.78 and a beta of 1.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, beating the consensus estimate of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The business had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million. Analysts expect that Cipher Pharmaceuticals will post 1.4156977 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.